A Randomized Phase II Study of Comparing Radiotherapy Alone With Concurrent Chemoradiation in Patients With Low Risk NK/T-cell Lymphoma
Radiotherapy alone is commonly used in NK/T-cell lymphoma without adverse risk including
lymph node involvement, local invasion, B symptoms and high LDH level. Recently,
methotrexate was prove to be a radiosensitizer in NK/T-cell lymphoma cells. Therefore, the
investigators aim to verify the superiority and safety of weekly methotrexate in combination
with radiotherapy in a randomized phase II study.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
3-year Progression-free survival
3 years
No
Ye Guo, MD
Principal Investigator
Fudan University
China: Ethics Committee
LMTG 12-01
NCT01667289
June 2012
June 2017
Name | Location |
---|